Singh et al. have undertaken a significant task in synthesising data from 55 trials and providing a useful overview of a complex pharmacological landscape 1. However, translating these statistical hierarchies to the bedside requires a closer look at several real-world variables. Including trials from as far back as 2000 results in the analysis crossing multiple eras of obstetric anaesthesia. Practice has moved on significantly from the high-dose spinal protocols and fluid pre-loading strategies that were common 20 years ago. Today's ultra-low-dose techniques and mandatory co-loading have fundamentally changed the physiological baseline of the obstetric patient 2. This ‘historical drift’ complicates the transitivity required for a network meta-analysis. It is worth considering whether the performance of newer drugs reflect their inherent properties or if they are simply benefiting from being studied in a more modern, optimised clinical environment. There is also the question of what is being measured. Singh et al. rely on umbilical artery pH and base excess to rank these drugs 1. While these numbers are staples of research, their clinical weight is often debated. Large-scale longitudinal studies suggest that these minor statistical shifts in cord gases are poor predictors of a child's actual neurodevelopmental trajectory 3. If a drug is ranked at the top, based on a marginal improvement in base excess that carries no proven benefit for the infant's long-term health, the clinical utility of the ranking becomes speculative. A vasopressor is only as effective as the protocol behind it. Evidence suggests that the precision of delivery, whether through weight-based regimens or automated systems, can influence outcomes as much as the molecule itself 4. By pooling manual boluses with modern infusion pumps, there is a risk of misattributing the success of a specific delivery method to the pharmacological drug being used. Ultimately, the history of this debate is marked by meta-analyses that yield ‘low to very low’ certainty of evidence 5. This persistent inconsistency suggests that more aggregate data synthesis may not be the answer. Perhaps it is time to shift focus towards large-scale, pragmatic trials that can isolate these confounding variables.
Kashmala Mushtaq (Tue,) studied this question.